Consensus estimates for Royalty Pharma (RPRX) ahead of its May 6, 2026, earnings report stand at $742.00 million in revenue and $1.22 in EPS, with the current stock price of $50.31 trading near the average analyst target of $53.03.
Investors are primarily focused on the company's 'Portfolio Receipts,' particularly the stability of its Cystic Fibrosis franchise amidst headwinds from generic competition for older assets.
Management's full-year 2026 guidance assumes a 3% to 8% growth in core royalty receipts, though total receipts may be dampened by a projected decline in milestone payments for the year. The report will also be the first full quarter reflecting the internalization of the external manager, a move expected to streamline governance and realize significant operational cost savings.